Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACITAC-001: CAR-T Therapy in Colombia for Recurrent/Refractory CD19+ Hematolymphoid Neoplasms
NCT07412405Not yet recruiting
- Sponsor
- Curexsys
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- CAR-T Cells
01
Overview
Open-label, single-arm trial of ARI-0001 in hematolymphoid neoplasm (HLN), non-Hodgkin lymphoma (NHL), B cell acute lymphoblastic leukemia (B-ALL) and 4 more, sponsored by Curexsys. Primary endpoint: Clinical Safety Outcome at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ARI-0001
03
Conditions
hematolymphoid neoplasm (HLN)non-Hodgkin lymphoma (NHL)B cell acute lymphoblastic leukemia (B-ALL)mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT07412405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412405.